30
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Insulin Action in the Vasculature: Physiology and Pathophysiology

      , ,
      Journal of Vascular Research
      S. Karger AG

      Read this article at

      ScienceOpenPublisher
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Studies to date have provided convincing evidence that insulin has an important role in the normal functioning of the vasculature from the perspective of the regulated delivery of nutrients to a tissue bed. This is mediated by an effect on the endothelium analogous to other endothelial responses, and insulin resistance is reflected in, and in part due to, impaired vasodilatory actions of insulin. Because insulin normally stimulates the net production of nitric oxide, which is beneficial in both the short term for vasomotion and antithrombosis, and the long term for inhibition of smooth muscle cell growth and migration, vascular insulin resistance also has important implications for vascular pathophysiology. Further, recent evidence suggests that the hyperinsulinemia accompanying insulin resistance may aggravate this situation by augmenting the endothelial production and release of endothelin-1. The investigation of insulin resistance in the vasculature provides not only a unique and physiologically relevant window onto vascular pathology, but also an opportunity for therapeutic targeting in individuals affected by the clinical states of insulin resistance. The present review highlights the importance of insulin sensitivity in the maintenance of endothelial function and explores the relationships between vascular insulin resistance and whole body glucose disposal. In addition, the recent evidence linking insulin to endothelin-1 production is discussed. Improving insulin sensitivity with insulin sensitizers such as rosiglitazone may represent an important advance in our ability to improve vascular dysfunction in diabetes.

          Related collections

          Most cited references10

          • Record: found
          • Abstract: not found
          • Article: not found

          Metformin.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Nitric oxide synthase: role in the genesis of vascular disease.

            The product of nitric oxide (NO) synthase is the most potent endogenous vasodilator known. No not only is a potent vasodilator, it also inhibits platelet adherence and aggregation, reduces adherence of leukocytes to the endothelium, and suppresses proliferation of vascular smooth muscle cells. A number of disorders are associated with reduced synthesis and/or increased degradation of vascular NO. These include hypercholesterolemia, diabetes mellitus, hypertension, and tobacco use. The endothelial dysfunction caused by these disorders contributes to the alterations in vascular function and structure observed in these conditions. A reduction in the activity of vascular NO likely plays a significant role in the development of atherosclerosis. Insights into the mechanisms by which NO production or activity is altered in these states will lead to new therapeutic strategies in the treatment of a number of vascular disorders, including hypertension, atherosclerosis, restenosis, and thrombosis.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              The Akt kinase signals directly to endothelial nitric oxide synthase

                Bookmark

                Author and article information

                Journal
                Journal of Vascular Research
                J Vasc Res
                S. Karger AG
                1018-1172
                1423-0135
                October 1 2001
                2001
                September 17 2001
                : 38
                : 5
                : 415-422
                Article
                10.1159/000051074
                1aa9c086-d0b3-4ef5-9a77-a813bb4032b0
                © 2001

                https://www.karger.com/Services/SiteLicenses

                https://www.karger.com/Services/SiteLicenses

                History

                Comments

                Comment on this article